EA201700214A1 - Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов - Google Patents

Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов

Info

Publication number
EA201700214A1
EA201700214A1 EA201700214A EA201700214A EA201700214A1 EA 201700214 A1 EA201700214 A1 EA 201700214A1 EA 201700214 A EA201700214 A EA 201700214A EA 201700214 A EA201700214 A EA 201700214A EA 201700214 A1 EA201700214 A1 EA 201700214A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nanoparticles
boron nitride
boron
antitumor
specific
Prior art date
Application number
EA201700214A
Other languages
English (en)
Other versions
EA033550B1 (ru
Inventor
Дмитрий Владимирович Штанский
Андрей Михайлович Ковальский
Андрей Трофимович МАТВЕЕВ
Ирина Викторовна Сухорукова
Наталия Александровна Глушанкова
Ирина Юрьевна Житняк
Original Assignee
Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" filed Critical Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС"
Publication of EA201700214A1 publication Critical patent/EA201700214A1/ru
Publication of EA033550B1 publication Critical patent/EA033550B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к области наномедицинских технологий, а именно к созданию нанотранспортеров лекарственных препаратов для противоопухолевой химиотерапии. Технический результат, достигаемый в предложенном изобретении, заключается в повышении эффективности противоопухолевой химиотерапии, в повышении активности поглощения клетками наноконтейнеров с противоопухолевым препаратом, предотвращении токсичности наноконтейнеров для клеток за счет применения диспергированных наночастиц нитрида бора размером 50-300 нм с развитой наружной поверхностью. Указанный технический результат достигается следующим образом. Способ получения наночастиц нитрида бора для доставки противоопухолевого препарата в опухолевые клетки включает синтез сферических наночастиц нитрида бора размером 50-300 нм с развитой наружной поверхностью методом химического осаждения из газовой фазы с применением реакционного газа, в качестве которого используют аммиак, транспортного газа, в качестве которого используют аргон, и порошковых смесей, состоящих из аморфного бора и реагент-окислителей. Химическое осаждение проводят при следующих условиях:где Т - температура порошковой смеси, °С; ξ - отношение удельных потоков газов F/F, где F- удельный поток транспортного газа; F- удельный поток реакционного газа. Далее проводят диспергирование агломератов полученных наночастиц нитрида бора методом ультразвуковой обработки. Затем осуществляют насыщение наночастиц нитрида бора противоопухолевым препаратом методом сорбции. Далее проводят промывку наночастиц нитрида бора в дистиллированной воде.
EA201700214A 2014-11-20 2015-02-04 Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов EA033550B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014146689/15A RU2565432C1 (ru) 2014-11-20 2014-11-20 Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов
PCT/RU2015/000064 WO2016080860A1 (en) 2014-11-20 2015-02-04 Method of boron nitride nanoparticle fabrication for antitumor drug delivery

Publications (2)

Publication Number Publication Date
EA201700214A1 true EA201700214A1 (ru) 2017-10-31
EA033550B1 EA033550B1 (ru) 2019-10-31

Family

ID=54327201

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700214A EA033550B1 (ru) 2014-11-20 2015-02-04 Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов

Country Status (9)

Country Link
US (1) US20170258724A1 (ru)
EP (1) EP3220960B1 (ru)
JP (1) JP6370491B2 (ru)
KR (1) KR101953684B1 (ru)
CN (1) CN107530444B (ru)
EA (1) EA033550B1 (ru)
IL (1) IL252319B (ru)
RU (1) RU2565432C1 (ru)
WO (1) WO2016080860A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2722745C1 (ru) * 2018-12-27 2020-06-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения наноконтейнеров для химиотерапевтических противоопухолевых препаратов

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2635865C1 (ru) * 2016-07-26 2017-11-16 Федеральное государственное бюджетное учреждение науки Ордена Ленина и Ордена Октябрьской революции Институт геохимии и аналитической химии им. В.И. Вернадского Российской академии наук (ГЕОХИ РАН) Способ получения наночастиц полистирольных ионообменников для доставки противоопухолевых препаратов
RU2720458C1 (ru) * 2019-06-06 2020-04-30 Автономное некоммерческое объединение "Международный научно-исследовательский центр инновационных технологий" (АНО "МНИЦИТ МАРТИНЕКС") Способ получения композиции для бор-нейтронозахватной терапии злокачественных опухолей (варианты)
KR102494639B1 (ko) * 2020-08-19 2023-02-02 내일테크놀로지 주식회사 나노 재료의 제조방법 및 장치
CN112972422A (zh) * 2021-03-04 2021-06-18 上海糖愈生物科技有限公司 一种肿瘤细胞膜仿生氮化硼纳米球及其制备方法和应用
CN115607668A (zh) * 2022-09-20 2023-01-17 山西医科大学 基于硼中子俘获治疗的富硼纳米制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976941B2 (en) * 1999-08-31 2011-07-12 Momentive Performance Materials Inc. Boron nitride particles of spherical geometry and process for making thereof
US7445797B2 (en) * 2005-03-14 2008-11-04 Momentive Performance Materials Inc. Enhanced boron nitride composition and polymer-based compositions made therewith
JP4277284B2 (ja) * 2002-05-24 2009-06-10 日立金属株式会社 微小体の製造方法および微小体
JP3851951B2 (ja) * 2002-12-05 2006-11-29 独立行政法人物質・材料研究機構 サブミクロンサイズの窒化ホウ素球状粒子の製造方法
EP1797155B1 (en) * 2004-08-23 2015-10-07 General Electric Company Thermally conductive composition and method for preparing the same
WO2009018092A1 (en) * 2007-07-27 2009-02-05 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
JP5105372B2 (ja) * 2009-02-03 2012-12-26 独立行政法人物質・材料研究機構 窒化ホウ素球状ナノ粒子とその製造方法
JP5448067B2 (ja) * 2009-12-09 2014-03-19 独立行政法人物質・材料研究機構 窒化ホウ素ナノチューブの製造方法
US9439941B2 (en) * 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
EP2667844B1 (en) * 2011-01-24 2018-11-21 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2722745C1 (ru) * 2018-12-27 2020-06-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения наноконтейнеров для химиотерапевтических противоопухолевых препаратов

Also Published As

Publication number Publication date
JP2018502827A (ja) 2018-02-01
EA033550B1 (ru) 2019-10-31
IL252319A0 (en) 2017-08-31
JP6370491B2 (ja) 2018-08-08
KR20170102870A (ko) 2017-09-12
EP3220960B1 (en) 2019-12-25
EP3220960A1 (en) 2017-09-27
RU2565432C1 (ru) 2015-10-20
US20170258724A1 (en) 2017-09-14
EP3220960A4 (en) 2018-07-04
IL252319B (en) 2021-04-29
WO2016080860A8 (en) 2017-06-15
CN107530444A (zh) 2018-01-02
WO2016080860A1 (en) 2016-05-26
CN107530444B (zh) 2019-04-19
KR101953684B1 (ko) 2019-03-04

Similar Documents

Publication Publication Date Title
EA201700214A1 (ru) Способ получения наночастиц нитрида бора для доставки противоопухолевых препаратов
MX2023005645A (es) Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
PL399505A1 (pl) Sposób wytwarzania zasadniczo czystych nanoczastek w ukladzie przeplywowym, nanoczastki otrzymane tym sposobem oraz ich zastosowanie
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
EA201171286A1 (ru) Новая технология изготовления индометацина
RU2014141365A (ru) Способ введения противоопухолевого агента
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
MX2013002155A (es) Compuestos para el tratamiento de cancer.
MY174074A (en) Method for producing silver particles
WO2011088456A3 (en) Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
PE20091924A1 (es) Compuesto peptidico y su uso
RU2012115543A (ru) Противоопухолевое средство
RU2013157868A (ru) Комбинированная фармацевтическая композиция для лечения опухолей
RU2010107158A (ru) Способ лечения экомодифицированного атопического дерматита у детей, проживающих в условиях воздействия техногенных химических факторов
MX2017014841A (es) Proceso para preparar compuestos basados en platino supramoleculares.
Sukhanova et al. " Mixer-dresser" hybrid device
Ilyasova et al. DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY ON 86 PREVIOUSLY UNTREATED PATIENTS
Zuo et al. Advances of MIR-492 studies in Cancers
Yamamoto et al. Enantioselective Azahelicenes via Intramolecular Hydroarylation of Alkynes
MX2017014281A (es) Composiciones de sulforafano y método para aumento de biodisponibilidad por técnicas ultrasónicas.
Mao Showcasing research from Professor Zong-Wan Mao’s Laboratory, School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou, China
MX2015014863A (es) Uso de metaloporfirinas funcionalizadas con l-glutamato como agente anticanerigeno en terapia fotodinamica contra el cancer.
EA201201655A1 (ru) Противоопухолевое средство (варианты)
UA59063U (ru) Способ получения удобрения на основе аддукта карбамида

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM RU